Initial evaluation of kinetics and efficacy of moxalactam (LY-127935) in neonatal systemic gram-negative bacterial disease

K. T. McKee, P. F. Wright, C. R. Gregg, C. W. Stratton

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Current antimicrobial therapy for systemic gram-negative bacterial infections during the newborn period is limited by the emergence of resistant strains and poor penetration of drugs into the central nervous system. Moxalactam, a new parenteral beta-lactam antibiotic, has an extended spectrum of coverage with good penetration of the blood-brain barrier. The pharmacokinetics and efficacy of moxalactam were studied in 5 neonates with serious gram-negative bacterial infections. Therapy was effective in all patients. In the dose employed (75 mg/kg/day), peak serum concentrations of 41.90 μg/ml were seen. Cerebrospinal fluid concentrations were 8-15% of simultaneous serum concentrations. In 4 patients without meningitis, and up to 69% of serum concentrations in one patient with inflamed meninges. Moxalactam deserves further evaluation in the therapy of systemic gram-negative bacterial infections in newborns.

Original languageEnglish (US)
Pages (from-to)603-610
Number of pages8
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume28
Issue number5 I
StatePublished - Jan 1 1980

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Initial evaluation of kinetics and efficacy of moxalactam (LY-127935) in neonatal systemic gram-negative bacterial disease'. Together they form a unique fingerprint.

  • Cite this